Journal article
Bladder Cancer Immunotherapy: BCG and Beyond
Advances in urology, Vol.2012, pp.181987-13
01/01/2012
DOI: 10.1155/2012/181987
PMCID: PMC3388311
PMID: 22778725
Abstract
Mycobacterium bovis bacillus Calmette-Guerin (BCG) has become the predominant conservative treatment for nonmuscle invasive bladder cancer. Its mechanism of action continues to be defined but has been shown to involve a T helper type 1 (Th1) immunomodulatory response. While BCG treatment is the current standard of care, a significant proportion of patients fails or do not tolerate treatment. Therefore, many efforts have been made to identify other intravesical and immunomodulating therapeutics to use alone or in conjunction with BCG. This paper reviews the progress of basic science and clinical experience with several immunotherapeutic agents including IFN-alpha, IL-2, IL-12, and IL-10.
Details
- Title: Subtitle
- Bladder Cancer Immunotherapy: BCG and Beyond
- Creators
- Eric J. Askeland - University of IowaMark R. Newton - University of IowaMichael A. O'Donnell - Univ Iowa, Dept Urol, 375 Newton Rd,3204 MERF, Iowa City, IA 52242 USAYi Luo - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Advances in urology, Vol.2012, pp.181987-13
- DOI
- 10.1155/2012/181987
- PMID
- 22778725
- PMCID
- PMC3388311
- NLM abbreviation
- Adv Urol
- ISSN
- 1687-6369
- eISSN
- 1687-6377
- Publisher
- Hindawi Publishing Group
- Number of pages
- 13
- Language
- English
- Date published
- 01/01/2012
- Academic Unit
- Urology
- Record Identifier
- 9984319992902771
Metrics
25 Record Views